Kornimate/medical-research-clean huggingface dataset:
alcohol, inflammation and atherosclerosis

Conditions: Arteriosclerosis; Myocardial Infarction

Summary: effect of moderate alcohol consumption in form of red wine, beer and ethanol solution and corresponding de-alcoholised beverages on immune measures. * in healthy middle aged men and women * in a randomized controlled cross-over trial * two intervention periods over 3 weeks

alcohol consumption and mortality from all causes are associated in a u-shaped manner. that means that individuals who regularly consume moderate amounts of alcohol (\~1 to 2 drinks/day at maximum) on average live longer than abstainers or heavy drinkers. this is primarily through a reduced risk for fatal or non-fatal coronary heart disease events (chd) such as myocardial infarction. in the last 10 to 15 years compelling evidence has bolstered the hypothesis that atherosclerosis is at least in part an inflammatory disease. it is also known, that alcohol influences the immune system. these facts make an impact of alcohol on the various stages of atherosclerosis via anti-inflammatory effects a reasonable assumption. to test the effect of moderate amounts of different types of alcoholic beverages on markers of inflammation with high predictive potential for atherothrombotic complications of atherosclerosis will be examined in a cross-over short-term interventional trial. six groups, each comprising 12 healthy individuals aged 22-56 will be included. after two weeks of abstinence from alcoholic beverages two cross-over interventional phases (each lasting 3 weeks) with red wine, beer, de-alcoholised red wine and beer of the same brand, ethanol, or water will follow. the interventions will be followed by a wash-out period of 2 weeks. several inflammatory markers and in-vitro migration of freshly isolated monocytes will be determined before and after intervention.

Eligibility criteria:
inclusion criteria: * 20-60 years * non-smoker * healthy exclusion criteria: * personal or family history of dependency * any chronic disease * acute and chronic inflammatory processes

Keywords: alcoholic beverages non-alcoholic beverages inflammation serum concentration of inflammatory markers before and after intervention
prospective evaluation of the efficacy of sirolimus (rapamune®) in the treatment of severe arteriovenous malformations

Conditions: Arteriovenous Malformations

Summary: the aim of the study is to evaluate the efficacy and safety of sirolimus (oral form), to decrease the volume and symptoms due to superficial arteriovenous malformations (avm). sirolimus has properties that reduce the activity of the immune system (immunosuppressant), to fight against the proliferation of cancer cells (anti- tumor) and also reduce the proliferation of blood vessels (anti -vascular). sirolimus is primarily used in transplant patients to prevent organ transplant rejection. many animal and laboratory studies were carried out and demonstrate in particular the activity of sirolimus on vessels. it is this anti- vascular effect that could help treat arteriovenous malformations.

anti-proliferative and anti-angiogenic properties of sirolimus (rapamycin®) are the basis of the rationale to use it in the treatment of arteriovenous malformations, for which the pathophysiology remains poorly understood. the interest of this class of drug is that inhibition of mtor (mammalian target of rapamycin) may also block growth and / or angiogenic factors (other than vegf) involved in the development of avm. more specifically anti-vegf drugs does not have that potential.

Eligibility criteria:
inclusion criteria: * patients (adults, adolescents and children older than 2 years), with arteriovenous malformation stage ii + iii or iv (according to schöbinger's classification) : active or quiescent, marked or not by hemorrhagic phenomena. * patients (parents for minors) must sign a consent form established after clear information risks and expected benefits of the study. * patients (major and minor of childbearing age) must have effective contraception during the study period and continuing until 12 weeks after the end of treatment * negative pregnancy blood test for women of childbearing age. exclusion criteria: * chronic or acquired immunosuppression : * patients with transplanted organ or who received a hematopoietic stem cell * patient with congenital immunodeficiency * patients implanted with chronic active infection associated with hepatitis b , hepatitis c or hiv * pregnant or nursing woman. * allergy to macrolides * allergy to peanut or soya * hypersensitivity to " sirolimus " or any of the excipients of the investigational product * contraindications to performing an mri * leukopenia below 1 000 /mm3 * thrombocytopenia lower to 80,000 /mm3 * anemia with hb \< 9 g/dl * elevated transaminase \> 2.5 n * history of cancer less than two years before the inclusion * surgery older than 2 months before inclusion * active infection (viral and bacterial ) on the date of inclusion * hypercholesterolemia \> 7 mmol / l despite appropriate medical treatment * hyperlipidemia \> 2 mmol / l despite appropriate medical treatment * uncontrolled diabetes * patients unable to follow a clinical study * major under guardianship, persons deprived of their liberty

Keywords: arteriovenous malformations sirolimus maxillofacial surgery
second generation colon capsule endoscopy (cce-2) in pediatric crohn's disease (cd).

Conditions: Pediatric; Colon Capsule Endoscopy

Summary: this prospective pilot study of 40 pediatric patients with crohn's disease, that are candidates for endoscopic and imaging re-evaluation, examines the given diagnostic system and the second generation of colon capsule in comparison second generation of colon capsule endoscopy (cce-2) to magnetic resonance enterography (mre), small intestine contrast ultrasonography (sicus) and endoscopy (upper and lower). this study aims 1. to evaluate and compare the accuracy of cce-2 with mre, sicus and endoscopy in the evaluation of pediatric crohn's disease. 2. to evaluate the safety of cce-2 in pediatric cd.


Eligibility criteria:
ages eligible for study: 6-18 years genders eligible for study: both accepts healthy volunteers: no inclusion criteria: subjects must meet one the following inclusion criteria to be eligible for enrollment into this proposed study: * diagnosis of crohn's disease made at least 3 months before the enrolment; * subject was referred for endoscopic and imaging follow-up in crohn's disease * signed informed consent. exclusion criteria the presence of any of the following will exclude a subject from study enrollment: * subject has dysphagia * subject has renal insufficiency * subject is known structuring crohn's disease identified by magnetic resonance enterography (mre) or small intestine contrast ultrasonography (sicus). * subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the magnetic resonance enterography findings and clinical judgment of the investigator.
evaluating a real-time, remote monitoring system for home-based hiv testing

Conditions: HIV

Summary: this study explores whether offering follow-up counseling and referral over the phone after using a home-based hiv test increases rates of ever and repeat testing, compared with home-based testing with no follow-up (hbst alone) or mailing reminders for clinic-based testing.


Eligibility criteria:
inclusion criteria: * sex with a partner met online in the past year * anal sex (either insertive or receptive) with a casual male partner in the past 6 months without using condoms or pre-exposure prophylaxis * own a smartphone (ios or android) with a service contract and data plan * have a stable address where mail can be received * speak english fluently exclusion criteria: * having tested for hiv in the last year

Keywords: hiv testing self-testing counseling referral
alleviating burden of chronic musculoskeletal pain in the emergency department

Conditions: Chronic Pain

Summary: chronic musculoskeletal pain (cmp) and lack of physical activity often co-exist, contributing to increased disability, non-communicable diseases (e.g., obesity, diabetes, hypertension), psychological comorbidity (e.g., anxiety and depression), and healthcare utilization and costs \[1-6\]. many individuals with cmp seek assistance at emergency departments (ed). ed overuse has been an ongoing concern, with 1-in-5 americans presenting to the ed at least once each year \[7\]. of these visits, 24 million are for adults seeking help for chronic pain, with an additional 12 million due to exacerbations of an existing chronic pain condition \[8\]. in 2021, the fourth most common reason for seeking care in the ed related to a primary diagnosis involving the musculoskeletal system, with an estimated 9.5 million visits \[9\]. most ed visits result in a 'treat and release' approach, potentially disrupting continuity of care and resulting in follow-up ed visits \[10\]. these ed visits for chronic pain are indicative of accessibility problems to community-based primary and preventative care, compounded by limited or no health insurance coverage \[10\]. based on the emergency medical treatment and labor act, eds are required to stabilize all patients regardless of ability to pay \[10\]. to alleviate the burden of cmp on patients and eds, improve access to quality healthcare, and mitigate initial and repeat ed visits, alternative options are required. here we propose a novel group-based intervention involving pain education (pe) and physical activity (pa) implemented in cmp patients presenting to the ed of a community level hospital. the investigators will recruit 60 adults from a community hospital located in the shenandoah valley region of virginia; participants will be randomized to either pain education and active knowledge (p.e.a.k.) rx (24 sessions of group pe+ + pa) or usual care. research assessments are conducted with both groups at study entry (baseline), 8-weeks, 3-months, and 6-months.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * sedentary (e.g., not meeting pa guidelines, assessed by acsm pa vitals) * english speaking and reading comprehension * not currently pregnant * diagnosed with cmp based on electronic health record: * non-red flag presentation (e.g., red flags: current fracture, malignancy, infection, vascular issues, or in need of surgical intervention). * persistent or recurrent pain for 3+ months, with at least moderate pain intensity level (visual analog scale of 40/100)

Keywords: musculoskeletal
feasibility of screening for early late effects of contemporary therapy in high-risk neuroblastoma survivors

Conditions: High-risk Neuroblastoma

Summary: the study participant is being asked to be in a research study called legacy, because you were treated for high-risk neuroblastoma (hr-nbl). primary objective to determine the feasibility of conducting comprehensive evaluations, leveraging the established sjlife (st. jude lifetime cohort study) study infrastructure, in survivors of hr-nbl (high-risk neuroblastoma) who are greater than 2 years from completion of contemporary therapy and were previously treated at sjcrh (st. jude children's research hospital). exploratory objectives * to describe the health outcomes of survivors of hr-nbl previously treated at sjcrh with contemporary era therapy who are greater than 2 years from completion of therapy. * to describe the relationship between patient outcomes and social determinants of health (sdoh) in survivors of hr-nbl previously treated at sjcrh with contemporary era therapy who are greater than 2 years from completion of therapy.

the study participant will have blood tests, tests to measure how your nervous system and stomach works, and an ultrasound of your liver for this study. the researchers will test how well your heart and blood vessels are working.

Eligibility criteria:
inclusion criteria: * participants were diagnosed with neuroblastoma at \< 18 years of age and categorized as high-risk at that time, according to inss26 or inrgss27 criteria. * participants were treated for hr-nbl at sjcrh on nb2012 or as per nb2012. * participants are ≥ 2 years from completion of therapy. participants are 5 years of age or older. * participant or legal guardian is able and willing to give informed consent. * participants may choose to participate in all or a fraction of the proposed assessments; refusal to participate in some aspects of the study will not preclude their inclusion. * participants must also complete enrollment on sjlife. exclusion criteria: * inability or unwillingness of research participant or legal guardian/representative to give written informed consent. * participants who had relapsed or refractory disease during or following completion of modern era treatment for hr-nbl. * participants who are pregnant or breastfeeding. * participants who are unable to read and understand english
molecular epidemiology of pediatric germ cell tumors

Conditions: Germ Cell Tumor; Germinoma; Teratoma; Embryonal Carcinoma; Yolk Sac Tumor; Choriocarcinoma; Mixed Germ Cell Tumor; Late Effects; Pediatric Germ Cell Tumor

Summary: a non-therapeutic study that aims to establish a cohort of gct survivors to understand short term and long-term adverse effects of treatment and to conduct molecular analyses to improve risk stratification.

primary objectives: i. establish a survivorship cohort for pediatric and adolescent gct comprised of participants from aepi10n1 and apec14b1 to assess short term and long-term adverse events associated with gct treatment. ii. compare somatic variation by tumor histology to identify molecular signatures that improve prognostic risk stratification. iii. identify methylation patterns that predict poor clinical outcomes, including disease relapse and death. outline: medical records from pediatric and adolescent germ cell tumor (gct) participants from aepi10n1 and apec14b1 will be used to obtain treatment information and validate self-reported outcomes. paired normal and tumor samples will be used to evaluate single nucleotide variants, indels, copy number variations, and dna methylation patterns. ototoxicity will be determined by central review of audiogram files obtained from the treating institutions and self-reported based on questionnaire data.

Eligibility criteria:
inclusion criteria: * cases will be eligible for the study if they have a primary diagnosis of gct including germinoma (iccc code105 9060-9065), teratoma (9080-9084), embryonal carcinoma (9070-9072), yolk sac tumor (9071), choriocarcinoma (9100, 9103, 9104), and mixed gct (9085, 9101, 9102, 9105) in all sites including the brain. * the patient must be enrolled on apec14b1 with consent to future contact or enrolled in aepi10n1 with consent for future contact (n=827). patients enrolled in aepi10n1 were recruited from accrn07. all patients must be registered with cog by a north american member institution. note: (history of) treatment on a cog therapeutic trial is not required. * patients must be diagnosed at \< 20 years of age at the time of gct diagnosis. study participants will be followed over time in the survivorship study so there is no maximum age for participation. * participants must be able to complete study related documents in english or spanish. * all patients and/or their parents or legal guardians must provide informed consent. assent will be obtained for participants between the ages of 8-17 years. * all institutional, fda, and nci requirements for human studies must be met. exclusion criteria: * participants from aepi10n1 who did not consent to future contact. patients who do not meet the eligibility criteria described above or cannot complete study materials in english or spanish
a phase iii study of the efficacy of taxotere/aptosyn versus taxotere/placebo in non-small cell lung cancer patients

Conditions: Non-Small Cell Lung Cancer

Summary: taxotere has been approved by the fda and is considered a standard treatment for patients with lung cancer who have failed prior platinum-containing regimens. the main purpose of this research study is to determine if aptosyn, when given in combination with taxotere, will result in prolonged survival when compared to taxotere alone. this study will also help determine tumor response rates, and the safety profile of aptosyn in combination with taxotere. this study has been completed and a publication is pending.


Eligibility criteria:
exclusion criteria:

Keywords: lung cancer nsclc non-small cell lung cancer
creatine safety, tolerability, & efficacy in huntington's disease (crest-e)

Conditions: Huntington's Disease

Summary: huntington's disease (hd) is a slowly progressive disorder that devastates the lives of those affected and their families. there are no treatments that slow the progression of hd, only mildly effective symptomatic therapies are available.creatine monohydrate is considered a nutritional supplement. the purpose of crest-e is to test whether high-dose creatine can slow the progressive functional decline that occurs in persons 18 years or older with early clinical features of hd. the long-term safety, tolerability and effectiveness of up to 40 grams daily creatine compared to placebo is studied. a variety of biological processes are assessed for markers of disease activity or progression and creatine effects. up to 50 active research centers globally will enroll 650 subjects.


Eligibility criteria:
inclusion criteria: * male or female ages 18 or older. * clinical features of hd and confirmatory family history of hd; or clinical features of hd and cag repeat expansion greater or equal to 36. * stage i or ii of illness (tfc greater or equal to 7). * ambulatory and not requiring skilled nursing care at the time of enrollment. * must be capable of providing informed consent and complying with trial procedures. * additional inclusion criteria apply. exclusion criteria: * history of known sensitivity or intolerability to creatine monohydrate. * exposure to any investigational drug within 30 days of randomization (baseline visit). * use of supplemental creatine at a dose greater than 10 grams within 30 days of randomization (baseline visit). * screening laboratory abnormalities that in the judgment of the investigator would jeopardize safe conduct of study. * clinical evidence of unstable medical illness. * clinical evidence of unstable psychiatric illness. * additional exclusion criteria apply.

Keywords: huntington's disease creatine mitochondrial dysfunction total functional capacity uhdrs
sensory cues for freezing in parkinson's disease

Conditions: Parkinson's Disease

Summary: the purpose of this study is (1) to determine if patient triggered sensory(auditory, visual and tactile) cues can help treat freezing of gait in parkinson's disease, and (2) to assess if unexpected (randomized) cues are more effective than anticipated ones.

freezing of gait (fog) is defined as a transient halt in motor activity, wherein the patient appears "as if nailed to the floor." it is a common phenomenon in parkinson's disease (pd), both when medications are at their peak ("on state") and at their lowest effectiveness ("off state"). while "off" fog often responds to dopaminergic medications, "on" fog is a difficult to treat, causing significant distress for the patient, and elevating risk of falls and morbidity. a few small studies have suggested that auditory and visual sensory cues, in the form of continuous stimuli such as a clicking metronome, music, or horizontal lines drawn the floor, may help patients with gait freezing. in this study, we aim to: (1) evaluate if stimuli (including visual, auditory as well as tactile cues) which are present only on patient triggering are effective for fog in pd; (2) investigate if presentation of unexpected cues, in the form of randomized sensory stimuli, are more effective that anticipated cues. participants will include patients diagnosed with pd, stabilized on drug therapy, with adequate vision, hearing, and mentation to respond to cuing, and experiencing "on" fog. patients will be evaluated during a single session. a small device which we have developed will be placed around the neck, and emit either repetitive beeping, a flashing line on the floor, or a slight vibration felt over the neck when the patient presses a button on the front panel in response to fog. participants will be videotaped walking a 15 m strip with: (1) no cues; (2) auditory cues only; (3) visual cues only; (4) tactile cues only; and (5) randomized cues. the order in which patients receive the cues will be randomized. a reviewer will watch the videotape with sound off so that they will be blinded to the cues. the total time, freezing time (duration of walk in which patient experiences freezing, walking time (duration of walk during which patient is not experiencing freezing), and average duration of freeze will be recorded for each walk.

Eligibility criteria:
inclusion criteria: * currently living in melbourne, australia (note that we cannot respond to enquiries from outside of this area) * confirmed diagnosis of parkinson's disease * stabilized drug therapy for at least 1 month prior to the study and during * hearing and vision - able to identify lines on floor, hear metronome * mmse \>24 * able to walk independently (with or without a mechanical aid) * able to give informed consent exclusion criteria: * severe comorbidity (joint problems, neuromuscular disorder affecting mobility) * severe dyskinesias

Keywords: freezing of gait parkinson's disease sensory cues
immediate versus delayed loading of single posterior zirconia implants

Conditions: Dental Implant Failed; Peri-implant Mucositis; Peri-Implantitis

Summary: the main aim of the present study is to investigate implant success rate after 5 years of function of immediate (test group; within 7 days of implant placement) versus delayed (control group; 8 weeks after implant placement) loading of two-pieces zirconia implant, placed in pristine bone without bone regeneration. implant success rate will be defined according to buser's criteria. secondary endpoints: marginal bone level (mbl) evaluation by means of standardized radiographs; clinical evaluation of biological (e.g. plaque index, pi; probing pocket depth, ppd, bleeding on probing, bop; suppuration upon probing/palpation) and prosthetic/technical complications; clinical evaluation of soft tissue width, keratinized tissue, marginal and interproximal soft tissue recession; patient reported outcome measures (proms) by questionnaire administration:


Eligibility criteria:
inclusion criteria: * sistemically healthy patients * partial edentulism * premolar position * molar position * bone width and height at least 6 and 10mm, respectively. * keratinized tissue, at least 1 mm at implant site * full understanding of the proposed surgical treatments and the protocol schedule * full comprehension and availability to sign the informed consent form exclusion criteria: * heavy smokers (\>10 cigarettes a day) * serious kidney or liver diseases * uncontrolled diabetes * bisphosphonates intake * history of radiotherapy of the head and neck * current antiblastic chemotherapy * congenital (primary) or acquired (secondary) immunodeficiency * pregnant women * connective tissue disorders local exclusion criteria: * untreated stage iii/iv periodontitis * autoimmune diseases * oral parafunctions